Diamino-diphenyl-sulfone, or dapsone, was the first antibiotic effective against leprosy [1] [2] [3] [4] [5] . Since dapsone was first used as monotherapy 20 years ago, resistance of Mycobacterium leprae to dapsone has increased to 80% among persons with relapsed cases (secondary resistance) and to 40% among persons with new cases (primary resistance) [2, 3, 6] . Beginning in 1982, multidrug therapy, that is, dapsone plus rifampin and clofazimine [7] has been used, whatever the degree of dapsone resistance. However, dapsone resistance is still commonly observed, although its prevalence is unknown; there have been only a few studies [8, 9] . Dapsone resistance is determined in vivo with the mouse footpad inoculation method [10], because M. leprae cannot be grown in vitro. In vivo tests require expertise to perform and are highly time consuming (it takes 7-
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Diamino-diphenyl-sulfone, or dapsone, was the first antibiotic effective against leprosy [1] [2] [3] [4] [5] . Since dapsone was first used as monotherapy 20 years ago, resistance of Mycobacterium leprae to dapsone has increased to 80% among persons with relapsed cases (secondary resistance) and to 40% among persons with new cases (primary resistance) [2, 3, 6] . Beginning in 1982, multidrug therapy, that is, dapsone plus rifampin and clofazimine [7] has been used, whatever the degree of dapsone resistance. However, dapsone resistance is still commonly observed, although its prevalence is unknown; there have been only a few studies [8, 9] . Dapsone resistance is determined in vivo with the mouse footpad inoculation method [10] , because M. leprae cannot be grown in vitro. In vivo tests require expertise to perform and are highly time consuming (it takes 7-12 months to get results). Dapsone resistance is classified phenotypically in 3 different levels: low (R-1), intermediate (R-10), or high (R-100), which refer, respectively, to the ability of the bacilli to multiply in mice fed with a diet containing 0.0001%, 0.001% or 0.01% dapsone [6, 11] . High and intermediate levels of dapsone resistance have been shown to correlate with clinical failure [3, 4, 6, 12, 13] . Secondary dapsone resistance is usually of a high or intermediate level, whereas primary resistance is usually of a low level [3, 4, 6] .
Molecular studies of drug resistance mechanisms in mycobacteria allowed for the development of molecular tools for detecting resistance to rifampin and fluoroquinolone in M. leprae [14] [15] [16] . As a sulfonamide derivative, dapsone is a competitive inhibitor of dihydropteroate synthase (DHPS) [1] . Recent studies have identified point mutations in the folP1 gene that encodes DHPS in dapsone-resistant M. leprae [17] [18] [19] .
Our objective was to evaluate the performance of molecular detection of mutations in the folP1 gene of M. leprae with respect to the prediction of in vivo dapsone resistance. We studied a large collection of M. leprae strains, isolated from patients with relapsed or new cases, that showed various levels of dapsone resistance, as well as dapsone-sensitive strains. For each M. leprae strain, results of the mouse footpad method were compared with those of the molecular method.
Methods. Thirty-eight strains of M. leprae were isolated from skin biopsy specimens obtained between 1987 and 2000 from patients living in the West Indies, Africa, Asia, and the Pacific who were diagnosed with multibacillary leprosy-either relapsed cases ( ) or new cases ( ). Biopsy specin p 17 n p 21 mens were obtained in the country of origin and sent to our laboratory for drug susceptibility testing. Preparation of skin biopsy samples and dapsone susceptibility testing with the standard mouse footpad inoculation method were performed as previously described [14] .
Genomic DNA was extracted from a 100-mL sample of the initial skin biopsy specimen suspension using the modified freeze-boiling technique [14] . A 900-base pair (bp) DNA fragment that corresponded to the whole folP1 gene (852 bp) was amplified as described by Kai et al. [17] . On the basis of the folP1 sequence, 2 other primers, 5 -GCTTCTCGTGCCGA-AGCGCTCG-3 and 5 -AGCCGACATCAGTCGCCAGTGC-3 , were designed to amplify a 450-bp fragment, starting from the 5 end of the gene and encompassing the sulfone resistancedetermining region. PCR reactions were as follows. Ten microliters of crude extract were added to 1 U Taq polymerase (Eurogentec) in a Taq buffer mixture containing 250 mM deoxy-nucleotide triphosphates, 500 nM primers each, and 2.5 mM MgCl 2 . This reaction mixture was incubated for 7 min at 94ЊC, and then PCR amplification was performed, consisting of 40 cycles of 1 min at 94ЊC, 1 min at 60ЊC, and 1 min at 72ЊC. PCR fragments purified using the Microcon procedure (Millipore) were subjected to direct sequencing, as described elsewhere [14] .
Results. On the basis of the results of the mouse footpad test, 22 strains of M. leprae were dapsone-sensitive and 16 were dapsone-resistant. Of the dapsone-resistant strains, 6 were classified as R-100, 4 as R-10, and 6 as R-1 (table 1) . Nine resistant strains were isolated from the 17 samples obtained from patients with relapsed cases (rate of secondary dapsone resistance, 53%) and 7 from the 21 samples obtained from patients with new cases (rate of primary dapsone resistance, 33%).
For all biopsy samples, PCR was positive for the 450-bp folP1 fragment, whereas only 50% of samples were positive for the 900-bp folP1 fragment. As shown in table 2, folP1 mutations were detected in 10 of the 16 dapsone-resistant strains (63% sensitivity). No mutations were detected in the 22 dapsonesusceptible strains (100% specificity). The mutations were observed in all 6 R-100 strains, in 3 of 4 R-10 strains, and in only 1 of 6 R-1 strains.
When calculated for the samples from the patients with relapsed cases ( ), the presence of a mutation in the folP1 n p 17 gene correlated with clinically relevant high or intermediate levels of resistance to dapsone: 7 of 7 strains with a mutation were classified as R-100 or R-10, and 10 of 10 strains without a mutation were susceptible or had R-1 resistance. This gives 100% positive predictive values and negative predictive values.
All mutations in the folP1 gene were missense mutations located at codon 53 (Thr53Ile, Thr53Arg and Thr53Ala) or codon 55 (Pro55Arg, Pro55Leu). Mutation Thr53Ile was detected in 3 strains, Thr53Ala was detected in 2 strains, Thr53Val was detected in 1 strain, Pro55Arg was detected in 2 strains, and Pro55Leu was detected in 2 strains.
Discussion. Mutation in the folP1 gene has been described as the molecular mechanism of dapsone resistance in M. leprae [17] [18] [19] . We assessed the feasibility and the clinical relevance of using a molecular test for the detection of folP1 mutation to predict dapsone resistance in 38 cases of leprosy that were chosen for sampling because of suspicion of resistance.
The folP1 mutations found in 10 M. leprae strains were the same as those described by other authors [17] [18] [19] . Williams et al. [20] hypothesized that Pro55Arg substitutions lead to a higher level of resistance to sulfonamides than do Thr53Ile substitutions, but this was not confirmed by our study, because Pro55 and Thr53 substitutions were equally observed in R-100 and R-10 strains. The predominant mechanism of sulfonamide resistance in bacteria and in eukaryotic organisms is mutation in the DHPS gene, either by insertion or by point mutation [1, 21, 22] . Comparison of the DHPS structures of Escherichia coli, Staphylococcus aureus, and Mycobacterium tuberculosis has shown that Thr62 and Pro64 (in the numbering system for E. coli, these locations correspond to Thr53 and Pro55 in M. leprae) may be the major site of interaction with sulfonamides in mycobacteria [22] [23] [24] [25] . The fact that no mutation has been found in 6 dapsone-resistant M. leprae strains, especially in 5 of 6 R-1 strains, suggests that other mechanisms might be involved, such as overproduction of p-aminobenzoic acid and decreased cell accumulation, which has been described in bacteria other than M. leprae [1] . Although porins and efflux mechanisms have been described in mycobacteria [26] [27] [28] [29] , the mechanisms of influx or efflux of sulfonamides have not been studied so far. Accumulation of several mechanisms of resistance could explain the levels of resistance to dapsone observed in M. leprae [2] [3] [4] 6] and could explain why DHPS mutations are more frequently observed in high-level resistant strains.
There is an unequivocal association between mutations in the M. leprae folP1 gene at codons 53 or 55 and dapsone resistance. In previous studies, folP1 mutations were observed in 14 of 15 R-100 strains, 1 of 5 R-10 strains, and 1 of 1 R-1 strain [17] [18] [19] . Our results demonstrated that the presence of the folP1 mutation is a specific predictor of dapsone resistance, because the 10 strains with mutations were dapsone-resistant, whereas the 22 dapsone-susceptible strains did not harbor mutations.
The limited sensitivity of the detection of a folP1 mutation for the prediction of dapsone resistance (63%) was mainly the result of the presence of R-1 strains among those studied, most of which were recovered from new cases of infection. The presence of strains with R-1 resistance is likely the result of contamination by relapsing patients who received dapsone at a low dosage, the way it was used at the beginning of dapsone therapy era. R-1 strains are no longer clinically relevant, because the standard dapsone dosage of 100 mg daily is now used in multidrug therapy [2, 6, 7] . Therefore, when specifically considering relapsed cases of leprosy, in which dapsone resistance is mainly classified as R-10 or R-100 [2, 6, 8, 9, 13] , the sensitivity of the detection of a folP1 mutation is excellent (100% positive predictive value). This result is new, because previous investigators did not stratify results according to whether cases were relapsed and new, except for Kai et al. [17] , who found a folP1 mutation in all 4 relapsed cases included in his study. A second important result is that the absence of a folP1 mutation in a relapsed case predicts the absence of R-10 or R-100 resistance (100% negative predictive value), because all strains without mutation isolated from such cases ( in our study) were n p 10 either dapsone-susceptible or R-1-resistant.
The performance of folP1 mutation detection for prediction of dapsone resistance allows for the definition of a therapeutic strategy. This strategy would be to search for folP1 mutations in patients with relapsed cases of multibacillary leprosy. If a missense folP1 mutation is observed at codon 53 or 55, it would be recommended to discontinue therapy with dapsone, because of a lack of expected benefit and risk of secondary effects and toxicity, and to replace it with therapy with another active drug, such as a fluoroquinolone [30] . If no mutation in the folP1 gene at codon 53 or 55 is observed, it would be recommended to maintain use of dapsone as part of the standard multidrug therapy. Such a strategy would be consistent with recommendations for tuberculosis therapy [31] . Molecular detection of dapsone resistance in M. leprae could be combined with the detection of rifampin resistance [14] in order to detect multidrug resistance in leprosy. 
